OHSONG PHARM Co., Ltd. (CEO, Young-Joong Kim) is expected to supply new products to the Japanese pharmaceutical market soon.
OHSONG PHARM has recently signed the agreement with N company which is a major Japanese pharmaceutical company to develop hyaluronic acid injection and started the sample production from late July.
So far, OHSONG PHARM has been well known as a penicillin export No.1 company to Japan though, the development and sales of hyaluronic acid products also have made it possible to line-up for new products other than penicillin.

The product of sodium hyaluronate has a mechanism of forming a film on cartilage tissue in the arthritis area and healing cartilage through lubrication and shock absorption. Also, it is growing steadily in the arthritis therapeutic market. In addition, the market response is expected to be further enhanced by the development of prefilled syringe formulations with enhanced usability.

As the sample production of hyaluronic acid products will be started in the second half of 2019, it is expected to be available to realease in Japan 2021 in earnest.

OHSONG PHARM has been steadily accumulating not only experience but know-how in the Japanese pharmaceutical market more than 10 years. Then, since OHSONG PHARM established Brio Pharma a Japanese subsidiary in 2017, they much more concentrated and targeted Japanese pharmaceutical market.

OHSONG PHARM will continue to introduce differentiated pharmaceuticals to the Japanese market, thereby solidifying its position as a leading company in Japan in the Korean pharmaceutical bio industry.